

FORM PTO-1390 (Modified) (REV 5-93)		U S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		079498/0146	
		U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.6)	
		Unassigned 09/701394	
INTERNATIONAL APPLICATION NO. PCT/US99/12799	INTERNATIONAL FILING DATE June 11, 1999	PRIORITY DATE CLAIMED June 12, 1998	
TITLE OF INVENTION MULTI-FLUORESCENT HAIRPIN ENERGY TRANSFER OLIGONUCLEOTIDES			
APPLICANT(S) FOR DO/EO/US Glenn Nardone			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.			
2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.			
3. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).			
4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19 th month from the earliest claimed priority date.			
5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))			
<input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).			
<input type="checkbox"/> has been transmitted by the International Bureau.			
<input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US)			
6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).			
7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))			
<input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).			
<input type="checkbox"/> have been transmitted by the International Bureau.			
<input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.			
<input checked="" type="checkbox"/> have not been made and will not be made.			
8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).			
9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).			
10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).			
Items 11. to 16. below concern other document(s) or information included:			
11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.			
12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.			
13. <input type="checkbox"/> A FIRST preliminary amendment.			
<input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.			
14. <input type="checkbox"/> A substitute specification.			
15. <input type="checkbox"/> A change of power of attorney and/or address letter.			
16. <input type="checkbox"/> Other items or information:			

09/701394

525 Rec'd PCT/PTO 04 DEC 2000

U.S. APPLICATION NO. (If known, see 37 CFR 1.50 Unassigned	INTERNATIONAL APPLICATION NO PCT/US99/12799	ATTORNEY'S DOCKET NUMBER 079498/0146					
17. <input checked="" type="checkbox"/> The following fees are submitted:		CALCULATIONS PTO USE ONLY					
Basic National Fee (37 CFR 1.492(a)(1)-(5): Search Report has been prepared by the EPO or JPO.....\$860.00							
International preliminary examination fee paid to USPTO (37 CFR 1.482).....\$690.00							
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)\$710.00							
Neither international preliminary examination fee (37 CFR 1.482) nor International search fee (37 CFR 1.445(a)(2)) paid to USPTO \$1,000.00							
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)\$100.00							
ENTER APPROPRIATE BASIC FEE AMOUNT =			\$860.00				
Surcharge of \$130.00 for furnishing the oath or declaration later than 20 Months from the earliest claimed priority date (37 CFR 1.492(e))			\$130.00				
Claims	Number Filed		Included in Basic Fee	Extra Claims	Rate		
Total Claims	74	-	20	= 54	× \$18.00	\$972.00	
Independent Claims	7	-	3	= 4	× \$80.00	\$320.00	
Multiple dependent claim(s) (if applicable)					\$270.00		
TOTAL OF ABOVE CALCULATIONS =					\$2282.00		
Reduction by ½ for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).					\$0.00		
SUBTOTAL =					\$2282.00		
Processing fee of \$130.00 for furnishing English translation later the 20 months from the earliest claimed priority date (37 CFR 1.492(f)).		+					
TOTAL NATIONAL FEE =					\$2282.00		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +							
TOTAL FEES ENCLOSED =					\$2282.00		
					Amount to be: refunded \$		
					charged \$		
a. <input checked="" type="checkbox"/>	A check in the amount of \$2282.00 to cover the above fees is enclosed.						
b. <input type="checkbox"/>	Please charge my Deposit Account No. <u>19-0741</u> in the amount of \$0.00 to the above fees. A duplicate copy of this sheet is enclosed.						
c. <input checked="" type="checkbox"/>	The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>19-0741</u> . A duplicate copy of this sheet is enclosed.						
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.							
SEND ALL CORRESPONDENCE TO:							
Foley & Lardner Washington Harbour 3000 K Street, N.W., Suite 500 Washington, D.C. 20007-5109				SIGNATURE  NAME STEPHEN A. BENT			
REGISTRATION NUMBER 29,768							

MULTI-FLUORESCENT HAIRPIN ENERGY TRANSFER OLIGONUCLEOTIDES

5

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention is broadly concerned with an oligonucleotide probe useful for detecting multiple target nucleic acid sequences in a sample. More particularly, the present invention relates to an oligonucleotide probe labeled with a molecular energy transfer (MET) trio including an energy donor and two energy acceptors which makes possible the detection of the multiple targets using only one excitation wavelength of light.

2. Description of the Related Art

The MET phenomenon is a process by which energy is passed between a donor molecule and an acceptor molecule. Fluorescence resonance energy transfer (FRET), which involves at least one fluorophore, is a form of MET. A fluorophore is a compound that absorbs light at one wavelength, and emits light at different wavelength. A spectrophotometer is used to simultaneously emit light which excites the fluorophore, and detect light emitted by the fluorophore. In FRET, the fluorophore is a donor molecule which absorbs photons, and subsequently transfers this energy to an acceptor molecule. Donor and acceptor molecules that engage in MET or FRET are termed MET pairs or FRET pairs, respectively. Förster, 1949, Z. Naturforsch A4:321-327; Clegg, 1992, Methods In Enzymology 211:353-388.

When two fluorophores are in close proximity, and the emission spectrum of the first fluorophore overlaps the excitation spectrum of the second fluorophore, excitation of the first fluorophore causes it to emit light that is absorbed by the second fluorophore, which in turn causes the second fluorophore to emit light. As a result, the fluorescence of the first fluorophore is quenched, while the fluorescence of the second fluorophore is enhanced. If the energy of the first fluorophore is transferred to a compound that is not a fluorophore, however, the fluorescence of the first fluorophore is quenched without subsequent emission of light by the non-fluorophore.

The FRET phenomenon has been exploited in methods for detecting nucleic acids. One of these methods is disclosed in U.S. patent No. 5,866,366, the entire contents of

which are herein incorporated by reference. The '366 patent discloses a FRET-labeled hairpin oligonucleotide which is used as a probe in polymerase chain reaction (PCR) methods to detect target nucleic acid sequences. This oligonucleotide contains an energy donor and an energy acceptor constituting a FRET pair. The donor and acceptor are 5 respectively situated on first and second nucleotide sequences of the oligonucleotide. These two nucleotide sequences are complementary to each other, and are therefore able to form a hairpin in the oligonucleotide.

If the first and second nucleotide sequences are annealed to each other, then the donor and acceptor are in close proximity. In this spatial arrangement, the acceptor 10 absorbs the emission from the donor, and thereby quenches the signal from the donor. However, if the nucleotide sequences are not annealed to each other, then the donor and acceptor are separated, the acceptor can no longer absorb the emission from the donor, and the signal from the donor is not quenched.

Thus, if the oligonucleotide is incorporated into an amplification product during 15 PCR, then the hairpin unfolds, resulting in the separation of the donor from the acceptor, and the consequent emission of an observable signal. However, if the oligonucleotide is not incorporated into a PCR amplification product, then the hairpin remains, and the emission from the donor is quenched by the acceptor. Detection of a signal after PCR therefore indicates the presence of the target.

20 Additionally, the FRET-labeled hairpin oligonucleotide described above may be used as a "molecular beacon" to detect a target nucleic acid sequence without incorporating it into a DNA molecule. The molecular-beacon technology is described in Tyagi et al., 1996, *Nature Biotechnology* 14:303-308, the entire contents of which are herein incorporated by reference. If the oligonucleotide hybridizes to a target, the hairpin 25 unfolds, and a detectable signal is generated. If the oligonucleotide does not hybridize to the target, the hairpin remains, and the signal is quenched. Detection of a signal after hybridization therefore indicates the presence of the target.

30 Detection of more than one target nucleic acid molecule in a single sample using the methods disclosed in the '366 patent and Tyagi et al. requires a FRET-labeled hairpin oligonucleotide specific to each target molecule, wherein each donor emits a distinctive signal. Since each donor typically must be excited by a different wavelength of light, it is necessary to irradiate the sample with multiple wavelengths of light. A major drawback to

this approach, however, is that it requires a spectrofluorimeter emitting a broad spectrum of light.

SUMMARY OF THE INVENTION

5 Avoiding the aforementioned drawback, the present invention is directed to a MET-labeled oligonucleotide, as well as to the use of this oligonucleotide to detect multiple target nucleic acid sequences in a single sample. Pursuant to this invention, multiple targets can be detected by irradiating a sample, containing the targets, with a single excitation wavelength of light.

10 An oligonucleotide according to the present invention contains three nucleotide sequences: a first nucleotide sequence, a second nucleotide sequence at the 5' end of the first nucleotide sequence, and a third nucleotide sequence at the 5' end of the second nucleotide sequence. Additionally, the oligonucleotide contains a MET trio, *e.g.*, a FRET trio, that includes an energy donor moiety and first and second energy acceptor moieties, where (i) the energy donor moiety is capable of emitting a quantum of energy and (ii) each of the first and second acceptor moieties is capable of absorbing a substantial amount of the quantum of energy. Preferably, the first acceptor moiety also is capable of emitting a quantum of energy.

15 The donor moiety is attached to a nucleotide of the first nucleotide sequence, the first acceptor moiety is attached to a nucleotide of the first nucleotide sequence, and the second acceptor moiety is attached to a nucleotide of the third nucleotide sequence, or, alternatively, the donor moiety is attached to a nucleotide of the third nucleotide sequence, the first acceptor moiety is attached to a nucleotide of the third nucleotide sequence, and the second acceptor moiety is attached to a nucleotide of the first nucleotide sequence.

20 The oligonucleotide is capable of forming a hairpin containing a nucleotide of the first nucleotide sequence and a nucleotide of the third nucleotide sequence. If the donor moiety emits the quantum of energy, then the first acceptor moiety absorbs a substantial amount of the emitted quantum of energy if, preferably only if, the hairpin is not formed, and the second acceptor moiety absorbs a substantial amount of the emitted quantum of energy if, preferably only if, the hairpin is formed.

25 An oligonucleotide of this invention preferably comprises a fourth nucleotide sequence at the 3' end of the first nucleotide sequence. Ideally, the third nucleotide

sequence is not complementary to the fourth nucleotide sequence, and the fourth nucleotide sequence is complementary to a nucleotide sequence flanking a target nucleotide sequence. *e.g.*, a DNA sequence. The oligonucleotide may be included in a kit containing a polymerase. The oligonucleotide preferably comprises a deoxyribonucleotide.

5 Advantageously, the donor moiety and the first acceptor moiety each are fluorophores, while the second acceptor moiety is a quencher of light emitted by the donor moiety. The preferred donor moiety, first acceptor moiety, and second acceptor moiety are fluorescein, 6-carboxy-X-rhodamine (ROX), and 4-(4'-dimethylamino-phenylazo) benzoic acid (DABSYL), respectively.

10 Preferably, there is (are) 0 to 50 nucleotide(s) in between the nucleotide to which the donor moiety is attached and the nucleotide to which the first acceptor moiety is attached, and there is (are) 0 to 50 nucleotide(s) in between the nucleotide to which the donor moiety is attached and the nucleotide to which the second acceptor moiety is attached. More preferably, there are 5 to 10 nucleotides in between the nucleotide to which the donor moiety is attached and the nucleotide to which the first acceptor moiety is attached, and there are 5 to 10 nucleotides in between the nucleotide to which the donor moiety is attached and the nucleotide to which the second acceptor moiety is attached.

15 20 Advantageously, if the hairpin is formed, then the nucleotide to which the donor moiety is attached is the complement of the nucleotide to which the second acceptor moiety is attached, or there is (are) 0 to 5 nucleotide(s) in between the nucleotide to which the donor moiety is attached and the complement of the nucleotide to which the second acceptor moiety is attached.

A preferred oligonucleotide comprises or consists of the nucleotide sequence of SEQ ID NO:1, wherein fluorescein is attached to the nucleotide at position 1 of SEQ ID NO:1, ROX is attached to the nucleotide at position 21 of SEQ ID NO:1, and DABSYL is attached to the nucleotide at position 5 or 10 of SEQ ID NO:1.

25 One method of the present invention is a method for determining if a target nucleotide sequence is present in a sample comprising the following steps:

30 In step (a), a sample is contacted with an oligonucleotide containing a first nucleotide sequence, a second nucleotide sequence at the 5' end of the first nucleotide sequence, and a third nucleotide sequence at the 5' end of the second nucleotide sequence. The oligonucleotide also contains a MET trio including an energy donor moiety, and first and second energy acceptor moieties, wherein the donor moiety is capable of emitting a

first quantum of energy, the first and second acceptor moieties are each capable of absorbing a substantial amount of the first quantum of energy, and the first acceptor moiety is capable of emitting a second quantum of energy. The preferred donor moiety, first acceptor moiety, and second acceptor moiety are fluorescein, ROX, and DABSYL,
5 respectively.

10 The donor moiety is attached to a nucleotide of the first nucleotide sequence, the first acceptor moiety is attached to a nucleotide of the first nucleotide sequence, and the second acceptor moiety is attached to a nucleotide of the third nucleotide sequence, or, alternatively, the first donor moiety is attached to a nucleotide of the third nucleotide
sequence, the first acceptor moiety is attached to a nucleotide of the third nucleotide sequence, and the second acceptor moiety is attached to a nucleotide of the first nucleotide sequence.

15 The oligonucleotide is capable of forming a hairpin containing a nucleotide of the first nucleotide sequence and a nucleotide of the third nucleotide sequence. If the donor moiety emits the first quantum of energy, then the first acceptor moiety absorbs a substantial amount of the emitted first quantum of energy if, preferably only if, the hairpin is not formed, and the second acceptor moiety absorbs a substantial amount of the emitted first quantum of energy if, preferably only if, the hairpin is formed.
20

In step (b), if the second quantum of energy is detected, then it is determined that the target nucleotide sequence is present in the sample, or if the second quantum of energy is not detected, then it is determined that the target nucleotide sequence is not present in the sample.

A second method of the present invention is a method for determining if a target nucleotide sequence is present in a sample comprising the following steps:

25 In step (a), a sample is contacted with an oligonucleotide containing a first nucleotide sequence, a second nucleotide sequence at the 5' end of the first nucleotide sequence, and a third nucleotide sequence at the 5' end of the second nucleotide sequence. The oligonucleotide also contains a MET trio including an energy donor moiety, and first and second energy acceptor moieties, wherein the donor moiety is capable of emitting a first quantum of energy, the first and second acceptor moieties are each capable of absorbing a substantial amount of the first quantum of energy, and the first acceptor moiety is capable of emitting a second quantum of energy. The preferred donor moiety,
30

first acceptor moiety, and second acceptor moiety are fluorescein, ROX, and DABSYL, respectively.

The donor moiety is attached to a nucleotide of the first nucleotide sequence, the first acceptor moiety is attached to a nucleotide of the first nucleotide sequence, and the 5 second acceptor moiety is attached to a nucleotide of the third nucleotide sequence, or, alternatively, the first donor moiety is attached to a nucleotide of the third nucleotide sequence, the first acceptor moiety is attached to a nucleotide of the third nucleotide sequence, and the second acceptor moiety is attached to a nucleotide of the first nucleotide sequence.

10 The oligonucleotide is capable of forming a hairpin containing a nucleotide of the first nucleotide sequence and a nucleotide of the third nucleotide sequence. If the donor moiety emits the first quantum of energy, then the first acceptor moiety absorbs a substantial amount of the emitted first quantum of energy if, preferably only if, the hairpin is not formed, and the second acceptor moiety absorbs a substantial amount of the emitted 15 first quantum of energy if, preferably only if, the hairpin is formed.

In step (b), the oligonucleotide is incorporated, preferably using a polymerase, into a double-stranded nucleic acid if the target nucleotide sequence is present in the sample, thereby preventing the hairpin from forming.

20 In step (c), which is optional, an amplification reaction is conducted, resulting in the incorporation of the oligonucleotide into an amplification product if the target nucleotide sequence is present in the sample.

25 In step (d), if the second quantum of energy is detected, then it is determined that the target nucleotide sequence is present in the sample, or if the second quantum of energy is not detected, then it is determined that the target nucleotide sequence is not present in the sample.

A third method of the present invention is a method for detecting a target nucleotide sequence comprising the following steps:

30 In step (a), a first oligonucleotide is annealed to a nucleotide sequence flanking a target nucleotide sequence, wherein the first oligonucleotide contains a first nucleotide sequence, a second nucleotide sequence at the 5' end of the first nucleotide sequence, and a third nucleotide sequence at the 5' end of the second nucleotide sequence. The first oligonucleotide also contains a MET trio including an energy donor moiety, and first and second energy acceptor moieties, wherein the donor moiety is capable of emitting a first

quantum of energy, and the first and second acceptor moieties are each capable of absorbing a substantial amount of the first quantum of energy. The preferred donor moiety, first acceptor moiety, and second acceptor moiety are fluorescein, ROX, and DABSYL, respectively.

5 The donor moiety is attached to a nucleotide of the first nucleotide sequence, the first acceptor moiety is attached to a nucleotide of the first nucleotide sequence, and the second acceptor moiety is attached to a nucleotide of the third nucleotide sequence, or, alternatively, the donor moiety is attached to a nucleotide of the third nucleotide sequence, the first acceptor moiety is attached to a nucleotide of the third nucleotide sequence, and 10 the second acceptor moiety is attached to a nucleotide of the first nucleotide sequence.

The first oligonucleotide is capable of forming a hairpin containing a nucleotide of the first nucleotide sequence and a nucleotide of the third nucleotide sequence. If the donor moiety emits the first quantum of energy, then the first acceptor moiety absorbs a substantial amount of the emitted first quantum of energy if, preferably only if, the hairpin 15 is not formed, and the second acceptor moiety absorbs a substantial amount of the emitted first quantum of energy if, preferably only if, the hairpin is formed.

The oligonucleotide advantageously comprises a fourth nucleotide sequence at the 3' end of the first nucleotide sequence. Ideally, the third nucleotide sequence is not complementary to the fourth nucleotide sequence, and the fourth nucleotide sequence is 20 complementary to a nucleotide sequence flanking a target nucleotide sequence.

In step (b), the 3' end of the first oligonucleotide is extended using the target nucleotide sequence as a template to form an extended first strand, wherein the target nucleotide sequence is annealed to the extended first strand.

In step (c), the target nucleotide sequence is separated from the extended first 25 strand.

In step (d), the second oligonucleotide is annealed to the extended first strand.

In step (e), the 3' end of the second oligonucleotide is extended using the extended first strand as a template to form an extended second strand, wherein the extended first strand is annealed to the extended second strand.

30 In step (f), which is optional, the extended first and second strands are amplified.

In step (g), a second quantum of energy emitted by the first acceptor moiety is detected to detect the target nucleotide sequence.

A variety of amplification methods can be used in step (f) to amplify the extended first and second strands (e.g., PCR amplification, strand displacement amplification, and cascade rolling circle amplification). The preferable method of amplification is PCR amplification comprising the following four steps:

- 5 In step (1), the extended first strand is separated from the extended second strand.
- In step (2), the first oligonucleotide is annealed to the extended second strand, and the second oligonucleotide is annealed to the extended first strand.
- In step (3), the 3' end of the first oligonucleotide is extended using the extended second strand as a template to form another extended first strand, wherein the extended second strand is annealed to the other extended first strand. Additionally, the 3' end of the second oligonucleotide is extended using the extended first strand as a template to form another extended second strand, wherein the extended first strand is annealed to the other extended second strand.
- 10 In step (4), steps (1), (2), and (3) are repeated for a finite number of times, wherein, in step (1), the extended first and second strands respectively are the extended first strand and the other extended second strand of step (3), or respectively are the other extended first strand and the extended second strand of step (3).
- 15 A fourth method of the present invention is a method for detecting a target nucleotide sequence comprising the following steps:
- 20 In step (a), a first oligonucleotide is annealed to a nucleotide sequence flanking a target nucleotide sequence, wherein the first oligonucleotide contains a first nucleotide sequence complementary to the nucleotide sequence flanking the target nucleotide sequence, and a second nucleotide sequence at the 5' end of the first nucleotide sequence.
- In step (b), the 3' end of the first oligonucleotide is extended using the target nucleotide sequence as a template to form an extended first strand, wherein the target nucleotide sequence is annealed to the extended first strand.
- 25 In step (c), the target nucleotide sequence is separated from the extended first strand.
- In step (d), a second oligonucleotide is annealed to the extended first strand.
- 30 In step (e), the 3' end of the second oligonucleotide is extended using the extended first strand as a template to form an extended second strand, wherein the extended first strand is annealed to the extended second strand.
- In step (f), the extended first strand is separated from the extended second strand.

In step (g), a third oligonucleotide is annealed to the extended second strand, wherein the third oligonucleotide contains a first nucleotide sequence, a second nucleotide sequence at the 5' end of the first nucleotide sequence, a third nucleotide sequence at the 5' end of the second nucleotide sequence, and a fourth nucleotide sequence at the 3' end of the first nucleotide sequence. The third oligonucleotide also contains a MET trio comprising an energy donor moiety, and first and second energy acceptor moieties. The donor moiety is capable of emitting a quantum of energy, and the first and second acceptor moieties are each capable of absorbing a substantial amount of the quantum of energy. The preferred donor moiety, first acceptor moiety, and second acceptor moiety are fluorescein, ROX, and DABSYL, respectively.

The donor moiety is attached to a nucleotide of the first nucleotide sequence, the first acceptor moiety is attached to a nucleotide of the first nucleotide sequence, and the second acceptor moiety is attached to a nucleotide of the third nucleotide sequence, or, alternatively, the donor moiety is attached to a nucleotide of the third nucleotide sequence, the first acceptor moiety is attached to a nucleotide of the third nucleotide sequence, and the second acceptor moiety is attached to a nucleotide of the first nucleotide sequence.

The third oligonucleotide is capable of forming a hairpin containing a nucleotide of the first nucleotide sequence and a nucleotide of the third nucleotide sequence, and if the donor moiety emits the quantum of energy, then the first acceptor moiety absorbs a substantial amount of the emitted quantum of energy if, preferably only if, the hairpin is not formed, and the second acceptor moiety absorbs a substantial amount of the emitted quantum of energy if, preferably only if, the hairpin is formed.

The fourth nucleotide sequence is complementary to the complement of the second sequence of the first oligonucleotide. Ideally, the third nucleotide sequence is not complementary to the fourth nucleotide sequence, and the fourth nucleotide sequence is complementary to a nucleotide sequence flanking a target nucleotide sequence.

In step (h), the 3' end of the third oligonucleotide is extended using the extended second strand as a template to form a doubly extended first strand, wherein the doubly extended first strand is annealed to the extended second strand.

In step (i), the doubly extended first strand is separated from the extended labeled second strand.

In step (j), the second oligonucleotide is annealed to the doubly extended first strand.

In step (k), the 3' end of the second oligonucleotide is extended using the doubly extended first strand as a template to form a doubly extended second strand, wherein the doubly extended first strand is annealed to the doubly extended second strand.

5 In step (l), which is optional, the doubly extended first and second strands are amplified.

In step (m), a second quantum of energy emitted by the first acceptor moiety is detected to detect the target nucleotide sequence.

10 A variety of amplification methods can be used in step (l) to amplify the extended first and second strands (*e.g.*, PCR amplification, strand displacement amplification, and cascade rolling circle amplification). The preferable method of amplification is PCR amplification comprising the following four steps:

In step (1), the doubly extended first strand is separated from the doubly extended second strand.

15 In step (2), the second oligonucleotide is annealed to the doubly extended first strand, and the third oligonucleotide is annealed to the doubly extended second strand.

In step (3), the 3' end of the second oligonucleotide is extended using the doubly extended first strand as a template to form another doubly extended second strand, wherein the doubly extended first strand is annealed to the other doubly extended second strand.

20 Additionally, the 3' end of the third oligonucleotide is extended using the doubly extended second strand as a template to form another doubly extended first strand, wherein the doubly extended second strand is annealed to the other doubly extended first strand.

25 In step (4), steps (1), (2), and (3) are repeated for a finite number of times, wherein, in step (1), the doubly extended first and second strands respectively are the doubly extended first strand and the other doubly extended second strand of step (3), or respectively are the other doubly extended first strand and the doubly extended second strand of step (3).

A fifth method of the present invention is a method for determining if a first or second target nucleotide sequence is present in a sample comprising the following steps:

30 In step (a), the sample is contacted with first and second oligonucleotides. The first oligonucleotide contains a first nucleotide sequence, a second nucleotide sequence at the 5' end of the first nucleotide sequence, and a third nucleotide sequence at the 5' end of the second nucleotide sequence. The first oligonucleotide also contains a MET trio including a first energy donor moiety, and first and second energy acceptor moieties, wherein the first

donor moiety is capable of emitting a first quantum of energy, and the first and second acceptor moieties are each capable of absorbing a substantial amount of the first quantum of energy.

The first donor moiety is attached to a nucleotide of the first nucleotide sequence,

5 the first acceptor moiety is attached to a nucleotide of the first nucleotide sequence, and the second acceptor moiety is attached to a nucleotide of the third nucleotide sequence, or, alternatively, the first donor moiety is attached to a nucleotide of the third nucleotide sequence, the first acceptor moiety is attached to a nucleotide of the third nucleotide sequence, and the second acceptor moiety is attached to a nucleotide of the first nucleotide

10 sequence.

The first oligonucleotide is capable of forming a first hairpin containing a nucleotide of the first nucleotide sequence and a nucleotide of the third nucleotide sequence. If the first donor moiety emits the first quantum of energy, then the first acceptor moiety absorbs a substantial amount of the emitted first quantum of energy if,

15 preferably only if, the first hairpin is not formed, and the second acceptor moiety absorbs a substantial amount of the emitted first quantum of energy if, preferably only if, the first hairpin is formed.

The second oligonucleotide contains a fourth nucleotide sequence, a fifth nucleotide sequence at the 5' end of the fourth nucleotide sequence, a sixth nucleotide sequence at the 20 5' end of the fifth nucleotide sequence. The second oligonucleotide also contains a MET pair including a second energy donor moiety and a third energy acceptor moiety, wherein the second donor moiety is capable of emitting a second quantum of energy, and the third acceptor moiety is capable of absorbing a substantial amount of the second quantum of energy.

25 The second donor moiety is attached to a nucleotide of the fourth nucleotide sequence and the third acceptor moiety is attached to a nucleotide of the sixth nucleotide sequence, or, alternatively, the second donor moiety is attached to a nucleotide of the sixth nucleotide sequence and the third acceptor moiety is attached to a nucleotide of the fourth nucleotide sequence.

30 The second oligonucleotide is capable of forming a second hairpin containing a nucleotide of the fourth nucleotide sequence and a nucleotide of the sixth nucleotide sequence. If the second donor moiety emits the second quantum of energy, then the third

acceptor moiety absorbs a substantial amount of the emitted second quantum of energy if, preferably only if, the second hairpin is formed.

The preferred first and second donor moieties each are fluorescein, the preferred first acceptor moiety is ROX, and the preferred second and third acceptor moieties each 5 are DABSYL. Ideally, the first oligonucleotide comprises a seventh nucleotide sequence at the 3' end of the first nucleotide sequence, the third nucleotide sequence is not complementary to the seventh nucleotide sequence, the seventh nucleotide sequence is complementary to a nucleotide sequence flanking the first target nucleotide sequence, the second oligonucleotide further comprises an eighth nucleotide sequence at the 3' end of the 10 fourth nucleotide sequence, the sixth nucleotide sequence is not complementary to the eighth nucleotide sequence, and the eighth nucleotide sequence is complementary to a nucleotide sequence flanking the second target nucleotide sequence.

In step (b) the first oligonucleotide is incorporated, preferably using a polymerase, into a first double-stranded nucleic acid if the first target nucleotide sequence is present in 15 the sample, thereby preventing the first hairpin from forming. Additionally, the second oligonucleotide is incorporated, preferably using a polymerase, into a second double-stranded nucleic acid if the second target nucleotide sequence is present in the sample, thereby preventing the second hairpin from forming.

In step (c), which is optional, a first amplification reaction is conducted, thereby 20 incorporating the first oligonucleotide into a first amplification product if the first target nucleotide sequence is present in the sample. Additionally, a second amplification reaction is conducted, thereby incorporating the second oligonucleotide into a second amplification product if the second target nucleotide sequence is present in the sample.

In step (d), it is determined that the first target nucleotide sequence is present in the 25 sample if a third quantum of energy emitted by the first acceptor moiety is detected, or it is determined that the first target nucleotide sequence is not present in the sample if the third quantum of energy is not detected. Additionally, it is determined that the second target nucleotide sequence is present in the sample if a fourth quantum of energy emitted by the third acceptor moiety is detected, or it is determined that the second target nucleotide 30 sequence is not present in the sample if the fourth quantum of energy is not detected.

Other objects, features, and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the description and the specific examples, while indicating preferred embodiments of the

invention, are given by way of illustration only, because various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

5

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

As explained above, the oligonucleotide of the present invention contains two nucleotide sequences that are capable of hybridizing to each other to form a hairpin. One nucleotide sequence contains an energy donor and first energy acceptor, while the other nucleotide sequence contains a second energy acceptor that is able to quench the signal generated by the donor. Thus, the present oligonucleotide contains a MET trio. In a preferred embodiment, the donor and first acceptor are fluorophores, the emission spectrum of the donor fluorophore overlaps the excitation spectrum of the acceptor fluorophore (*i.e.*, the first acceptor), and the second acceptor is a quencher of the signal emitted by the donor fluorophore.

15 In accordance with the present invention, the donor fluorophore and the quencher are positioned on the oligonucleotide so that, if the hairpin is formed, then the donor fluorophore is in close proximity to the quencher, and energy emitted by the donor fluorophore is absorbed by the quencher, resulting in quenching of the signal from the donor fluorophore. If the hairpin is not formed, however, and the quencher consequently 20 does not absorb the energy emitted by the donor, then the emitted energy is absorbed by the acceptor fluorophore, and is subsequently emitted by the acceptor fluorophore as a detectable signal.

Pursuant to the present invention, detection of a target nucleic acid sequence in a sample occurs in one of at least two ways. First, the oligonucleotide may be incorporated 25 into an amplification product which contains the target sequence. Second, the oligonucleotide may be hybridized to the target sequence. In a preferred embodiment, irradiation of the sample, using a spectrofluorimeter after such incorporation or hybridization, causes the acceptor fluorophore to emit a signal which is detected by the spectrofluorimeter. Thus, signal detection indicates that the target is present, while the 30 absence of a signal indicates that the target is not present.

A sample is assayed for the presence of two targets by using the oligonucleotide described above in conjunction with another oligonucleotide. The other oligonucleotide

also contains two nucleotide sequences capable of forming a hairpin, along with a donor fluorophore and a quencher positioned, with respect to the hairpin, as in the present oligonucleotide. The donors of the present oligonucleotide and the other oligonucleotide are excited by the same or approximately the same wavelength of light. However, the 5 other oligonucleotide does not contain the acceptor fluorophore, and therefore contains a MET pair rather than a MET trio. The present oligonucleotide and other oligonucleotide are specific to the first and second targets, respectively.

If the sample contains both the first and second targets, then a hairpin is prevented from forming in both the present oligonucleotide and the other oligonucleotide after the 10 amplification or hybridization reactions are conducted. Subsequent irradiation of the sample with a single wavelength of light that excites the donor fluorophore of the present oligonucleotide and the other oligonucleotide, but not the acceptor fluorophore of the present oligonucleotide, causes two distinctive signals to be generated. The first signal is emitted by the acceptor moiety of the present oligonucleotide, while the second signal is emitted by the donor fluorophore of the other oligonucleotide. Thus, the first target is 15 detected by observing the first signal, while the second target is detected by observing the second signal. Two targets therefore can be detected by irradiating the sample with only one wavelength of light.

The invention is further described by reference to the examples below, which are set 20 forth by illustration only. Nothing therein should be taken as a limitation upon the overall scope of the invention.

Example 1

Spectroscopic analysis of model FRET-labeled hairpin oligonucleotides

25 each containing a donor fluorophore, an acceptor fluorophore, and a quencher

A total of seven oligonucleotides were synthesized. All of these oligonucleotides have the following nucleotide sequence: 5'-ACCGATGCGTTGAGCATCGGTGAAGGTC-GGAGTCAACGGATT-3' (SEQ ID NO:1). All of the oligonucleotides contain a fluorescein moiety (*i.e.*, the first fluorophore) attached to the nucleotide at position 1 and a 30 DABSYL moiety attached to the nucleotide at position 21. Oligonucleotides 1 through 4 each contain a second fluorophore attached to the nucleotide at position 5, while oligonucleotides 5 through 7 each contain a second fluorophore attached to the nucleotide at position 10. The second fluorophore in oligonucleotides 1 and 5 is N,N,N',N'-

tetramethyl-6-carboxyrhodamine (TAMRA), in oligonucleotides 3 and 6 is ROX, in oligonucleotides 4 and 7 is Texas Red, and in oligonucleotide 2 is Bodipy 564/570.

The fluorescein and DABSYL moieties were incorporated into each oligonucleotide during their synthesis using a dA-fluorescein phosphoramidite and a dU-DABSYL phosphoramidite, respectively. Additionally, a hexylamine moiety was attached to the carbon atom at the 5 position of the base moiety of the nucleotides at position 5 of oligonucleotides 1 through 4, and at position 10 of oligonucleotides 5 through 7. This hexylamine moiety was incorporated into each oligonucleotide during their synthesis using a dU-hexylamine phosphoramidite.

After the oligonucleotides were synthesized as described above, each oligonucleotide was deprotected, desalted, and purified by reverse-phase high-performance liquid chromatography using C18 silica and triethylamine acetate-acetonitrile gradients. The appropriate fractions were subsequently pooled, precipitated using acetone, dried under vacuum, dissolved, and desalted.

The hexylamine residue of each oligonucleotide was then labeled with the appropriate fluorophore containing an N-succinimidyl ester or an isothiocyanate moiety in a solution of sodium bicarbonate buffer, pH 9, 20% dimethyl sulfoxide at room temperature for approximately 20 hours. Each oligonucleotide was subsequently precipitated using acetone, dried under vacuum, dissolved, and desalted.

For spectroscopic analysis of each of the oligonucleotides, four to five picomoles of oligonucleotide were dissolved in a volume of 0.6 ml. Each oligonucleotide solution was analyzed using a Shimadzu RFU 5000 analytical spectrofluorimeter. To induce the closed confirmation, in which the oligonucleotide contains a hairpin, the oligonucleotide was dissolved in annealing buffer containing 10 mM Tris-HCl, pH 8, 3 mM MgCl₂, and 50 mM NaCl. The open confirmation, in which the hairpin is absent, was induced by adding a molar excess of a complementary, unlabeled oligonucleotide to each oligonucleotide in annealing buffer, heating the solution at 90°C for three minutes, and cooling the solution to room temperature.

The fluorescein moiety of each oligonucleotide in the open and closed conformations was excited by irradiation. Table 1 below demonstrates that such irradiation results in a substantial light emission from the second fluorophore of each oligonucleotide in the open conformation. In the closed conformation, however, each oligonucleotide shows little second-fluorophore emission at fluorescein excitation wavelengths.

Table 1

oligo-nucleotide	second fluorophore	excitation wavelength (nm) ¹ / emission wavelength (nm) ²	fluorescence per picomole in closed conformation (relative fluorescence units)	fluorescence per picomole in open conformation (relative fluorescence units)
1	TAMRA	495/588	6	28
2	Bodipy 564/570	495/598	7	48
3	ROX	495/605	3	34
4	Texas Red	495/620	5	26
5	TAMRA	495/588	7	30
6	ROX	495/605	4	18
7	Texas Red	495/620	4	30

¹ Wavelength of light exciting fluorescein.

² Wavelength of light emitted from the second fluorophore; the wavelength of each second-

5 fluorophore emission is substantially different from the peak wavelength of fluorescein emission (516 nm).

Example 2

Detection of two target nucleic acid sequences in PCR amplification using a hairpin oligo-nucleotide containing a FRET trio and a hairpin oligonucleotide containing a FRET pair

A sample is assayed for the presence of mRNA encoded by a prostate-specific antigen (PSA) gene. As a control to insure that a PCR reaction can be conducted in the sample, a quantity of cDNA specific to the glyceraldehyde-3-phosphate dehydrogenase (gapDH) gene is added to the sample.

15 The hairpin oligonucleotides are used as forward primers during PCR. The nucleotide sequence of the forward primer specific to the gapDH cDNA is 5'-AGCGATGCGTCGAGCATCGCTGAAGGTCGGAGTCAACGGATT-3' (SEQ ID NO:2), wherein the nucleotides at positions 1 and 22 are labeled with fluorescein and DABSYL, respectively, and the nucleotide at position 5 or 10 is labeled with TAMRA.

20 The nucleotide sequence of the hairpin primer specific to the PSA mRNA is

5'-AGCGATGCGTCGAGCATCGCTGAAGGTGACCAAGTCAT-3' (SEQ ID NO:3), wherein the nucleotides at positions 1 and 22 are labeled with fluorescein and DABSYL, respectively. The nucleotide sequences of the reverse primers specific to the gapDH cDNA and the PSA mRNA are 5'-GGATCTCGCTCCTGGAAGATGGT-3' (SEQ ID NO:4), and 5'-GGTGTACAGGGAAGGCCTTCGGGAC-3' (SEQ ID NO:5), respectively.

Each PCR reaction sample contains, in a 0.2 ml PCR reaction tube, 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl₂, 250 μ M dNTPs, 0.25 μ M of each forward primer, 0.25 μ M of each reverse primer, gapDH cDNA, and 2 units of Taq polymerase in 50 μ l. A control sample additionally contains PSA mRNA, which, for example, is produced by LNCaP tissue-culture cells available from the American Type Culture Collection, Manassas, VA.

Each reaction tube is placed in a thermocycler such as an ABI 7700 real-time instrument, or a Perkin Elmer 9600 or 9700. The cycle program is as follows: [94°C, 4 min.]-[94°C, 15 sec.; 55°C, 30 sec.; 72°C, 1 min] for 35 cycles - [72°C, 5 min] - [4°C, hold]. The progress of gapDH cDNA amplification is followed directly by observing the emission of light having a wavelength of 580 nm (*i.e.*, the emission from TAMRA), while the progress of PSA mRNA amplification is followed directly by observing the emission of light having a wavelength of 530 nm (the emission from fluorescein). End-point analysis is effected by means of a fluorescent plate reader, such as a Wallac Victor equipped with filters that allow detection of 530-nm and 580-nm light.

This application claims priority from U.S. provisional application serial No. 60/089,119, entitled "MULTI-FLUORESCENT HAIRPIN ENERGY TRANSFER OLIGONUCLEOTIDES," which was filed on June 12, 1998. The entire contents of this application are incorporated herein by reference.

WE CLAIM:

1. An oligonucleotide containing:

(a) a first nucleotide sequence,

(b) a second nucleotide sequence at the 5' end of the first nucleotide sequence,

5 (c) a third nucleotide sequence at the 5' end of the second nucleotide sequence, and

(d) a molecular energy transfer trio including an energy donor moiety, and first and second energy acceptor moieties,

wherein:

10 the energy donor moiety is capable of emitting a quantum of energy, and the first and second acceptor moieties are each capable of absorbing a substantial amount of the quantum of energy,

15 the donor moiety is attached to a nucleotide of the first nucleotide sequence, the first acceptor moiety is attached to a nucleotide of the first nucleotide sequence, and the second acceptor moiety is attached to a nucleotide of the third nucleotide sequence; or the donor moiety is attached to a nucleotide of the third nucleotide sequence, the first acceptor moiety is attached to a nucleotide of the third nucleotide sequence, and the second acceptor moiety is attached to a nucleotide of the first nucleotide sequence,

20 the oligonucleotide is capable of forming a hairpin containing a nucleotide of the first nucleotide sequence and a nucleotide of the third nucleotide sequence, and

if the donor moiety emits the quantum of energy, then:

(1) the first acceptor moiety absorbs a substantial amount of the emitted quantum of energy if the hairpin is not formed, and

(2) the second acceptor moiety absorbs a substantial amount of the emitted quantum of energy if the hairpin is formed.

25

2. The oligonucleotide of claim 1, wherein the first acceptor moiety absorbs the substantial amount of the emitted quantum of energy only if the hairpin is not formed.

30 3. The oligonucleotide of claim 1, wherein the second acceptor moiety absorbs the substantial amount of the emitted quantum of energy only if the hairpin is formed.

4. The oligonucleotide of claim 1, comprising a deoxyribonucleotide.

5. The oligonucleotide of claim 1, further comprising a fourth nucleotide sequence at the 3' end of the first nucleotide sequence.

6. The oligonucleotide of claim 5, wherein the third nucleotide sequence is not 5 complementary to the fourth nucleotide sequence.

7. The oligonucleotide of claim 5, wherein the fourth nucleotide sequence is complementary to a nucleotide sequence flanking a target nucleotide sequence.

10 8. The oligonucleotide of claim 7, wherein the target nucleotide sequence is DNA.

9. The oligonucleotide of claim 1, wherein the donor moiety is a fluorophore.

15 10. The oligonucleotide of claim 1, wherein the first acceptor moiety is a fluorophore.

11. The oligonucleotide of claim 9, wherein the second acceptor moiety is a quencher of light emitted by the fluorophore.

20 12. The oligonucleotide of claim 1, wherein the first acceptor moiety is capable of emitting another quantum of energy.

13. The oligonucleotide of claim 1, wherein the donor moiety is fluorescein.

25 14. The oligonucleotide of claim 1, wherein the first acceptor moiety is ROX.

15. The oligonucleotide of claim 1, wherein the second acceptor moiety is DABSYL.

30 16. The oligonucleotide of claim 1, wherein there is (are) 0 to 50 nucleotide(s) in between the nucleotide to which the donor moiety is attached and the nucleotide to which the first acceptor moiety is attached.

17. The oligonucleotide of claim 16, wherein there are 5 to 10 nucleotides in between the nucleotide to which the donor moiety is attached and the nucleotide to which the first acceptor moiety is attached.

5 18. The oligonucleotide of claim 1, wherein there is (are) 0 to 50 nucleotide(s) in between the nucleotide to which the donor moiety is attached and the nucleotide to which the second acceptor moiety is attached.

10 19. The oligonucleotide of claim 18, wherein there are 5 to 10 nucleotides in between the nucleotide to which the donor moiety is attached and the nucleotide to which the second acceptor moiety is attached.

15 20. The oligonucleotide of claim 1, wherein, if the hairpin is formed, then the nucleotide to which the donor moiety is attached is the complement of the nucleotide to which the second acceptor moiety is attached.

20 21. The oligonucleotide of claim 1, wherein, if the hairpin is formed, then there is (are) 0 to 5 nucleotide(s) in between the nucleotide to which the donor moiety is attached and the complement of the nucleotide to which the second acceptor moiety is attached.

25 22. An oligonucleotide comprising the nucleotide sequence of SEQ ID NO:1, wherein fluorescein is attached to the nucleotide at position 1 of SEQ ID NO:1, ROX is attached to the nucleotide at position 21 of SEQ ID NO:1, and DABSYL is attached to the nucleotide at position 5 or 10 of SEQ ID NO:1.

23. The oligonucleotide of claim 22 consisting of the nucleotide sequence of SEQ ID NO:1.

24. A kit comprising the oligonucleotide of claim 1 and a polymerase.

30 25. The kit of claim 24, wherein the polymerase is a DNA polymerase.

26. A method for determining if a target nucleotide sequence is present in a sample comprising:

(a) contacting the sample with an oligonucleotide containing:

(1) a first nucleotide sequence,

5 (2) a second nucleotide sequence at the 5' end of the first nucleotide sequence,

(3) a third nucleotide sequence at the 5' end of the second nucleotide sequence, and

10 (4) a molecular energy transfer trio including an energy donor moiety, and first and second energy acceptor moieties,

wherein:

the donor moiety is capable of emitting a first quantum of energy,

15 the first and second acceptor moieties are each capable of absorbing a substantial amount of the first quantum of energy,

the first acceptor moiety is capable of emitting a second quantum of energy,

20 the donor moiety is attached to a nucleotide of the first nucleotide sequence, the first acceptor moiety is attached to a nucleotide of the first nucleotide sequence, and the second acceptor moiety is attached to a nucleotide of the third nucleotide sequence; or the first donor moiety is attached to a nucleotide of the third nucleotide sequence, the first acceptor moiety is attached to a nucleotide of the third nucleotide sequence, and the second acceptor moiety is attached to a nucleotide of the first nucleotide sequence,

25 the oligonucleotide is capable of forming a hairpin containing a nucleotide of the first nucleotide sequence and a nucleotide of the third nucleotide sequence, and

30 if the donor moiety emits the first quantum of energy, then the first acceptor moiety absorbs a substantial amount of the emitted first quantum of energy if the hairpin is not formed, and the second acceptor moiety absorbs a substantial amount of the emitted first quantum of energy if the hairpin is formed, and

(b) if the second quantum of energy is detected, then determining that the target nucleotide sequence is present in the sample; or if the second quantum of energy is not detected, then determining that the target nucleotide sequence is not present in the sample.

27. The method of claim 26, wherein the first acceptor moiety absorbs the substantial amount of the emitted first quantum of energy only if the hairpin is not formed.

28. The method of claim 26, wherein the second acceptor moiety absorbs the 5 substantial amount of the emitted first quantum of energy only if the hairpin is formed.

29. The method of claim 26, wherein the donor moiety is fluorescein.

30. The method of claim 26, wherein the first acceptor moiety is ROX.

10

31. The method of claim 26, wherein the second acceptor moiety is DABSYL.

32. A method for determining if a target nucleotide sequence is present in a sample comprising:

15 (a) contacting the sample with an oligonucleotide containing:

(1) a first nucleotide sequence,

(2) a second nucleotide sequence at the 5' end of the first nucleotide sequence,

(3) a third nucleotide sequence at the 5' end of the second nucleotide sequence, and

20 (4) a molecular energy transfer trio including an energy donor moiety, and first and second energy acceptor moieties,

wherein:

the donor moiety is capable of emitting a first quantum of energy,

25 the first and second acceptor moieties are each capable of absorbing a substantial amount of the first quantum of energy,

the first acceptor moiety is capable of emitting a second quantum of energy,

30 the donor moiety is attached to a nucleotide of the first nucleotide sequence, the first acceptor moiety is attached to a nucleotide of the first nucleotide sequence, and the second acceptor moiety is attached to a nucleotide of the third nucleotide sequence; or the first donor moiety is attached to a nucleotide of the third nucleotide sequence, the first acceptor moiety is attached to a

nucleotide of the third nucleotide sequence, and the second acceptor moiety is attached to a nucleotide of the first nucleotide sequence,

the oligonucleotide is capable of forming a hairpin containing a nucleotide of the first nucleotide sequence and a nucleotide of the third nucleotide sequence, and

5 if the donor moiety emits the first quantum of energy, then the first

acceptor moiety absorbs a substantial amount of the emitted first quantum of energy if the hairpin is not formed, and the second acceptor moiety absorbs a substantial amount of the emitted first quantum of energy if the hairpin is formed,

(b) incorporating the oligonucleotide into a double-stranded nucleic acid if the target nucleotide sequence is present in the sample, thereby preventing the hairpin from forming,

(c) optionally conducting an amplification reaction, thereby incorporating the oligonucleotide into an amplification product if the target nucleotide sequence is present in the sample, and

(d) if the second quantum of energy is detected, then determining that the target nucleotide sequence is present in the sample; or if the second quantum of energy is not detected, then determining that the target nucleotide sequence is not present in the sample.

33. The method of claim 32, wherein the first acceptor moiety absorbs the substantial amount of the emitted first quantum of energy only if the hairpin is not formed.

20

34. The method of claim 32, wherein the second acceptor moiety absorbs the substantial amount of the emitted first quantum of energy only if the hairpin is formed.

25 35. The method of claim 32, wherein the oligonucleotide further comprises a

fourth nucleotide sequence at the 3' end of the first nucleotide sequence.

36. The method of claim 35, wherein the third nucleotide sequence is not complementary to the fourth nucleotide sequence.

30 37. The method of claim 35, wherein the fourth nucleotide sequence is complementary to a nucleotide sequence flanking the target nucleotide sequence.

38. The method of claim 32, wherein the donor moiety is fluorescein.

39. The method of claim 32, wherein the first acceptor moiety is ROX.

40. The method of claim 32, wherein the second acceptor moiety is DABSYL.

5 41. The method of claim 32, wherein, in (b), the oligonucleotide is incorporated into the double-stranded nucleic acid using a polymerase.

42. A method for detecting a target nucleotide sequence comprising:

(a) annealing a first oligonucleotide to a nucleotide sequence flanking a target 10 nucleotide sequence, wherein the first oligonucleotide contains:

(1) a first nucleotide sequence,

(2) a second nucleotide sequence at the 5' end of the first nucleotide sequence,

(3) a third nucleotide sequence at the 5' end of the second nucleotide sequence, and

(4) a molecular energy transfer trio including an energy donor moiety, and first and second energy acceptor moieties,

wherein:

the donor moiety is capable of emitting a first quantum of energy,

20 the first and second acceptor moieties are each capable of absorbing a substantial amount of the first quantum of energy,

the donor moiety is attached to a nucleotide of the first nucleotide sequence, the first acceptor moiety is attached to a nucleotide of the first nucleotide sequence, and the second acceptor moiety is attached to a nucleotide of the third nucleotide sequence; or the donor moiety is attached to a nucleotide of the third nucleotide sequence, the first acceptor moiety is attached to a nucleotide of the third nucleotide sequence, and the second acceptor moiety is attached to a nucleotide of the first nucleotide sequence,

30 the first oligonucleotide is capable of forming a hairpin containing a nucleotide of the first nucleotide sequence and a nucleotide of the third nucleotide sequence, and

if the donor moiety emits the first quantum of energy, then the first acceptor moiety absorbs a substantial amount of the emitted first quantum of

energy if the hairpin is not formed, and the second acceptor moiety absorbs a substantial amount of the emitted first quantum of energy if the hairpin is formed,

(b) extending the 3' end of the first oligonucleotide using the target nucleotide

sequence as a template to form an extended first strand, wherein the target nucleotide

5 sequence is annealed to the extended first strand,

(c) separating the target nucleotide sequence from the extended first strand,

(d) annealing a second oligonucleotide to the extended first strand,

(e) extending the 3' end of the second oligonucleotide using the extended first strand

as a template to form an extended second strand, wherein the extended first strand is

10 annealed to the extended second strand,

(f) optionally amplifying the extended first and second strands, and

15 (g) detecting a second quantum of energy emitted by the first acceptor moiety to detect the target nucleotide sequence.

43. The method of claim 42, wherein the first acceptor moiety absorbs the substantial amount of the emitted first quantum of energy only if the hairpin is not formed.

44. The method of claim 42, wherein the second acceptor moiety absorbs the substantial amount of the emitted first quantum of energy only if the hairpin is formed.

20 45. The method of claim 42, wherein (f) comprises:

(1) separating the extended first strand from the extended second strand,

25 (2) annealing the first oligonucleotide to the extended second strand, and annealing the second oligonucleotide to the extended first strand,

(3) extending the 3' end of the first oligonucleotide using the extended second strand as a template to form another extended first strand, wherein the extended second strand is annealed to the other extended first strand; and extending the 3' end of the second oligonucleotide using the extended first strand as a template to form another extended second strand, wherein the extended first strand is annealed to the other extended second strand, and

30 (4) repeating (1), (2), and (3) for a finite number of times, wherein, in (1), the extended first and second strands respectively are the extended first strand and the other

extended second strand of (3), or respectively are the other extended first strand and the extended second strand of (3).

46. The method of claim 42, wherein the oligonucleotide further comprises a

5 fourth nucleotide sequence at the 3' end of the first nucleotide sequence.

47. The method of claim 46, wherein the third nucleotide sequence is not complementary to the fourth nucleotide sequence.

10 48. The method of claim 46, wherein the fourth nucleotide sequence is complementary to the nucleotide sequence flanking the target nucleotide sequence.

49. The method of claim 42, wherein the donor moiety is fluorescein.

15 50. The method of claim 42, wherein the first acceptor moiety is ROX.

51. The method of claim 42, wherein the second acceptor moiety is DABSYL.

52. A method for detecting a target nucleotide sequence comprising:

20 (a) annealing a first oligonucleotide to a nucleotide sequence flanking a target nucleotide sequence, wherein the first oligonucleotide contains:

(1) a first nucleotide sequence complementary to the nucleotide sequence flanking the target nucleotide sequence, and

(2) a second nucleotide sequence at the 5' end of the first nucleotide sequence,

25 (b) extending the 3' end of the first oligonucleotide using the target nucleotide sequence as a template to form an extended first strand, wherein the target nucleotide sequence is annealed to the extended first strand,

(c) separating the target nucleotide sequence from the extended first strand,

30 (d) annealing a second oligonucleotide to the extended first strand,

(e) extending the 3' end of the second oligonucleotide using the extended first strand as a template to form an extended second strand, wherein the extended first strand is annealed to the extended second strand,

(f) separating the extended first strand from the extended second strand,
(g) annealing a third oligonucleotide to the extended second strand, wherein the third oligonucleotide contains:

5 (1) a first nucleotide sequence,
sequence,
(2) a second nucleotide sequence at the 5' end of the first nucleotide
sequence,
(3) a third nucleotide sequence at the 5' end of the second nucleotide
sequence,
(4) a fourth nucleotide sequence at the 3' end of the first nucleotide
sequence, and
10 (5) a molecular energy transfer trio comprising an energy donor moiety,
and first and second energy acceptor moieties,
wherein:
the fourth nucleotide sequence is complementary to the complement of the
second sequence of the first oligonucleotide,
the donor moiety is capable of emitting a quantum of energy,
15 the first and second acceptor moieties are each capable of absorbing a
substantial amount of the quantum of energy,
the donor moiety is attached to a nucleotide of the first nucleotide
20 sequence, the first acceptor moiety is attached to a nucleotide of the first
nucleotide sequence, and the second acceptor moiety is attached to a nucleotide of
the third nucleotide sequence; or the donor moiety is attached to a nucleotide of the
third nucleotide sequence, the first acceptor moiety is attached to a nucleotide of the
third nucleotide sequence, and the second acceptor moiety is attached to a
25 nucleotide of the first nucleotide sequence,
the third oligonucleotide is capable of forming a hairpin containing a
nucleotide of the first nucleotide sequence and a nucleotide of the third nucleotide
sequence, and
30 if the donor moiety emits the quantum of energy, then the first acceptor
moiety absorbs a substantial amount of the emitted quantum of energy if the
hairpin is not formed; and the second acceptor moiety absorbs a substantial
amount of the emitted quantum of energy if the hairpin is formed,

(h) extending the 3' end of the third oligonucleotide using the extended second strand as a template to form a doubly extended first strand, wherein the doubly extended first strand is annealed to the extended second strand,

5 (i) separating the doubly extended first strand from the extended labeled second strand,

(j) annealing the second oligonucleotide to the doubly extended first strand,

(k) extending the 3' end of the second oligonucleotide using the doubly extended first strand as a template to form a doubly extended second strand, wherein the doubly extended first strand is annealed to the doubly extended second strand,

10 (l) optionally amplifying the doubly extended first and second strands, and

(m) detecting a second quantum of energy emitted by the first acceptor moiety to detect the target nucleotide sequence.

15 53. The method of claim 52, wherein the first acceptor moiety absorbs a substantial amount of the emitted quantum of energy only if the hairpin is not formed.

54. The method of claim 52, wherein the second acceptor moiety absorbs a substantial amount of the emitted quantum of energy only if the hairpin is formed.

20 55. The method of claim 52, wherein (l) comprises:

(1) separating the doubly extended first strand from the doubly extended second strand,

(2) annealing the second oligonucleotide to the doubly extended first strand, and annealing the third oligonucleotide to the doubly extended second strand,

25 (3) extending the 3' end of the second oligonucleotide using the doubly extended first strand as a template to form another doubly extended second strand, wherein the doubly extended first strand is annealed to the other doubly extended second strand; and extending the 3' end of the third oligonucleotide using the doubly extended second strand as a template to form another doubly extended first strand, wherein the doubly extended

30 second strand is annealed to the other doubly extended first strand, and

(4) repeating (1), (2), and (3) for a finite number of times, wherein, in (1), the doubly extended first and second strands respectively are the doubly extended first strand

and the other doubly extended second strand of (3), or respectively are the other doubly extended first strand and the doubly extended second strand of (3).

56. The method of claim 52, wherein the third nucleotide sequence is not
complementary to the fourth nucleotide sequence.

57. The method of claim 52, wherein the fourth nucleotide sequence is
complementary to the nucleotide sequence flanking the target nucleotide sequence.

10 58. The method of claim 52, wherein the donor moiety is fluorescein.

59. The method of claim 52, wherein the first acceptor moiety is ROX.

60. The method of claim 52, wherein the second acceptor moiety is DABSYL.

15 61. A method for determining if a first or second target nucleotide sequence is
present in a sample comprising:

(a) contacting the sample with:

(1) a first oligonucleotide containing:

20 (i) a first nucleotide sequence,

(ii) a second nucleotide sequence at the 5' end of the first
nucleotide sequence,

(iii) a third nucleotide sequence at the 5' end of the second
nucleotide sequence, and

25 (iv) a molecular energy transfer trio including a first energy
donor moiety, and first and second energy acceptor moieties,

wherein:

the first donor moiety is capable of emitting a first quantum of
energy,

30 the first and second acceptor moieties are each capable of
absorbing a substantial amount of the first quantum of energy,

the first donor moiety is attached to a nucleotide of the first
nucleotide sequence, the first acceptor moiety is attached to a nucleotide

of the first nucleotide sequence, and the second acceptor moiety is attached to a nucleotide of the third nucleotide sequence; or the first donor moiety is attached to a nucleotide of the third nucleotide sequence, the first acceptor moiety is attached to a nucleotide of the third nucleotide sequence, and the second acceptor moiety is attached to a nucleotide of the first nucleotide sequence,

5 the first oligonucleotide is capable of forming a first hairpin containing a nucleotide of the first nucleotide sequence and a nucleotide of the third nucleotide sequence, and

10 if the first donor moiety emits the first quantum of energy, then the first acceptor moiety absorbs a substantial amount of the emitted first quantum of energy if the first hairpin is not formed, and the second acceptor moiety absorbs a substantial amount of the emitted first quantum of energy if the first hairpin is formed, and

15 (2) a second oligonucleotide containing:

(i) a fourth nucleotide sequence,
(ii) a fifth nucleotide sequence at the 5' end of the fourth nucleotide sequence,

20 (iii) a sixth nucleotide sequence at the 5' end of the fifth nucleotide sequence, and

(iv) a molecular energy transfer pair including a second energy donor moiety and a third energy acceptor moiety,

25 wherein:

the second donor moiety is capable of emitting a second quantum of energy,

the third acceptor moiety is capable of absorbing a substantial amount of the second quantum of energy,

30 the second donor moiety is attached to a nucleotide of the fourth nucleotide sequence and the third acceptor moiety is attached to a nucleotide of the sixth nucleotide sequence, or the second donor moiety is attached to a nucleotide of the sixth nucleotide sequence and the third acceptor moiety is attached to a nucleotide of the fourth nucleotide sequence,

the second oligonucleotide is capable of forming a second hairpin containing a nucleotide of the fourth nucleotide sequence and a nucleotide of the sixth nucleotide sequence, and

5 if the second donor moiety emits the second quantum of energy, then the third acceptor moiety absorbs a substantial amount of the emitted second quantum of energy if the second hairpin is formed,

(b) incorporating:

10 (1) the first oligonucleotide into a first double-stranded nucleic acid if the first target nucleotide sequence is present in the sample, thereby preventing the first hairpin from forming, and

(2) the second oligonucleotide into a second double-stranded nucleic acid if the second target nucleotide sequence is present in the sample, thereby preventing the second hairpin from forming,

15 (c) optionally conducting:

(1) a first amplification reaction, thereby incorporating the first oligonucleotide into a first amplification product if the first target nucleotide sequence is present in the sample, and

20 (2) a second amplification reaction, thereby incorporating the second oligonucleotide into a second amplification product if the second target nucleotide sequence is present in the sample, and

(d) determining that:

25 (1) the first target nucleotide sequence is present in the sample if a third quantum of energy emitted by the first acceptor moiety is detected, or the first target nucleotide sequence is not present in the sample if the third quantum of energy is not detected, and

(2) the second target nucleotide sequence is present in the sample if a fourth quantum of energy emitted by the third acceptor moiety is detected, or the second target nucleotide sequence is not present in the sample if the fourth quantum of energy is not detected.

30

62. The method of claim 61, wherein the first acceptor moiety absorbs a substantial amount of the emitted first quantum of energy only if the first hairpin is not formed.

63. The method of claim 61, wherein the second acceptor moiety absorbs a substantial amount of the emitted first quantum of energy only if the first hairpin is formed.

5 64. The method of claim 61, wherein the third acceptor moiety absorbs a substantial amount of the emitted second quantum of energy only if the second hairpin is formed.

10 65. The method of claim 61, wherein the first oligonucleotide further comprises a seventh nucleotide sequence at the 3' end of the first nucleotide sequence.

15 66. The method of claim 65, wherein the third nucleotide sequence is not complementary to the seventh nucleotide sequence.

67. The method of claim 65, wherein the seventh nucleotide sequence is complementary to a nucleotide sequence flanking the first target nucleotide sequence.

68. The method of claim 61, wherein the second oligonucleotide further comprises an eighth nucleotide sequence at the 3' end of the fourth nucleotide sequence.

20 69. The method of claim 67, wherein the sixth nucleotide sequence is not complementary to the eighth nucleotide sequence.

70. The method of claim 67, wherein the eighth nucleotide sequence is complementary to a nucleotide sequence flanking the second target nucleotide sequence.

71. The method of claim 61, wherein the first and second donor moieties are each fluorescein.

30 72. The method of claim 61, wherein the first acceptor moiety is ROX.

73. The method of claim 61, wherein the second and third acceptor moieties are each DABSYL.

74. The method of claim 61, wherein, in (b), the first oligonucleotide is incorporated into the first double-stranded nucleic acid using a polymerase, and the second oligonucleotide is incorporated into the second double-stranded nucleic acid using a polymerase.

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I HEREBY DECLARE:

THAT my residence, post office address, and citizenship are as stated below next to my name;

THAT I believe I am the original, first, and sole inventor (if only one inventor is named below) or an original, first, and joint inventor (if plural inventors are named below or in an attached Declaration) of the subject matter which is claimed and for which a patent is sought on the invention entitled

MULTI-FLUORESCENT HAIRPIN ENERGY TRANSFER OLIGONUCLEOTIDES

(Attorney Docket No. 079498/0146)

the specification of which (check one)

 is attached hereto.

 X

was filed on June 11, 1999 as United States Application Number or PCT International Application Number PCT/US99/12799 and was amended on _____ (if applicable).

THAT I do not know and do not believe that the same invention was ever known or used by others in the United States of America, or was patented or described in any printed publication in any country, before I (we) invented it;

THAT I do not know and do not believe that the same invention was patented or described in any printed publication in any country, or in public use or on sale in the United States of America, for more than one year prior to the filing date of this United States application;

THAT I do not know and do not believe that the same invention was first patented or made the subject of an inventor's certificate that issued in any country foreign to the United States of America before the filing date of this United States application if the foreign application was filed by me (us), or by my (our) legal representatives or assigns, more than twelve months (six months for design patents) prior to the filing date of this United States application;

THAT I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment specifically referred to above;

THAT I believe that the above-identified specification contains a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention, and sets forth the best mode contemplated by me of carrying out the invention; and

THAT I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I HEREBY CLAIM foreign priority benefits under Title 35, United States Code §119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number	Country	Foreign Filing Date	Priority Claimed?	Certified Copy Attached?

I HEREBY CLAIM the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

U.S. Provisional Application Number	Filing Date
60/089,119	June 12, 1998

I HEREBY CLAIM the benefit under Title 35, United States Code, §120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Application Number	Parent Filing Date	Parent Patent Number

I HEREBY APPOINT the following registered attorneys and agents of the law firm of FOLEY & LARDNER:

STEPHEN A. BENT	Reg. No. <u>29,768</u>
DAVID A. BLUMENTHAL	Reg. No. <u>26,257</u>
BETH A. BURROUS	Reg. No. <u>35,087</u>
ALAN I. CANTOR	Reg. No. <u>28,163</u>
WILLIAM T. ELLIS	Reg. No. <u>26,874</u>
JOHN J. FELDHAUS	Reg. No. <u>28,822</u>
PATRICIA D. GRANADOS	Reg. No. <u>33,683</u>
JOHN P. ISACSON	Reg. No. <u>33,715</u>
MICHAEL D. KAMINSKI	Reg. No. <u>32,904</u>

22

LYLE K. KIMMS	Reg. No. <u>34,079</u>
KENNETH E. KROSIN	Reg. No. <u>25,735</u>
JOHNNY A. KUMAR	Reg. No. <u>34,649</u>
GLENN LAW	Reg. No. <u>34,371</u>
PETER G. MACK	Reg. No. <u>26,001</u>
BRIAN J. MC NAMARA	Reg. No. <u>32,789</u>
SYBIL MELOY	Reg. No. <u>22,749</u>
RICHARD C. PEET	Reg. No. <u>35,792</u>
GEORGE E. QUILLIN	Reg. No. <u>32,792</u>
BERNHARD D. SAXE	Reg. No. <u>28,665</u>
CHARLES F. SCHILL	Reg. No. <u>27,590</u>
RICHARD L. SCHWAAB	Reg. No. <u>25,479</u>
HAROLD C. WEGNER	Reg. No. <u>25,258</u>

to have full power to prosecute this application and any continuations, divisions, reissues, and reexaminations thereof, to receive the patent, and to transact all business in the United States Patent and Trademark Office connected therewith.


I request that all correspondence be directed to:

Stephen A. Bent
 FOLEY & LARDNER
 Washington Harbour
 3000 K Street, N.W., Suite 500
 Washington, D.C. 20007-5109

Telephone: (202) 672-5404
 Facsimile: (202) 672-5399

I UNDERSTAND AND AGREE THAT the foregoing attorneys and agents appointed by me to prosecute this application do not personally represent me or my legal interests, but instead represent the interests of the legal owner(s) of the invention described in this application.

I FURTHER DECLARE THAT all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

1 - 00 Name of first inventor Glenn Nardone
 Residence Oakton, Virginia VA
 Citizenship United States
 Post Office Address 11735 Stuart Mill Road
Oakton, Virginia 22124
 Inventor's signature 
 Date 1/2/01